MET elevation	Squamous Cell Carcinoma of Head and Neck	MET elevation	Squamous Cell Carcinoma of Head and Neck	cetuximab + AV-299 Resistant: C3 – Early Trials cetuximab + AV-299 Resistant : C3	cetuximab + AV-299 Resistant: C3 – Early Trials cetuximab + AV-299 Resistant : C3
MET overexpression	Squamous Cell Carcinoma of Head and Neck	MET overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab + AV-299 Sensitive: C3 – Early Trials cetuximab + AV-299 Sensitive : C3	cetuximab + AV-299 Sensitive: C3 – Early Trials cetuximab + AV-299 Sensitive : C3
FLT3 G697R	Acute Myelogenous Leukemia	FLT3 G697R	Acute Myelogenous Leukemia	K-252a Sensitive: D – Preclinical K-252a Sensitive : D	K-252a Sensitive: D – Preclinical K-252a Sensitive : D

Hepatocyte growth factor inhibitor

Associations(3)